The Role of Tumor Mutational Burden in Lung Cancer
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video LibraryDrs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Related Videos

Common Issues in Treating Patients with HR+/ HER2-Negative Metastatic Breast Cancer
Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.
Knowing and Treating Obscure GI Tumors
Phillip Boudreaux, MD, talks about how gastrointestinal tumors can be masked and not diagnosed as the primary cause of why some patients are morbidly sick.